Abstract 360P
Background
Breast cancer is the the most frequently diagnosed cancer worldwide in women, with nearly two million new cases diagnosed in 2018. In the Philippines, breast cancer is the most common cancer among women. Upon diagnosis, the decision process differs from person to person. The patients then meet choices about surgical treatment and the need for adjuvant treatment, taking into consideration surgery, chemotherapy and radiation therapy to name a few. However, these decisions are not clear cut and a thorough discussion between the patient and the physician regarding treatment options taking into consideration the choice of the patient. This study aims to identify factors influencing treatment decisions among breast cancer patients in the Philippine General Hospital Cancer Institute - Medical Oncology Outpatient Clinic.
Methods
The study used a questionnaire and structured interview adapted from study done by Grunfeld, et.al. Descriptive statistics were utilized in the analysis of the data acquired from the recruited participants. This allowed identification of patient demographics, economic profile, cancer profile, sources of financial or medical assistance and summary of patient’s responses to identify the factors influencing treatment decisions among breast cancer patients.
Results
A total of 272 participants consented and included in the analysis of the study. This study identified high level of satisfaction with consultation to their attending physician, caring and sincere communication about prognosis and likelihood of benefit from treatment, family as person of influence, patient’s collaborative role in the decision-making process, desire of cure and trust with their doctors as factors of influence in accepting cancer treatment decisions.
Conclusions
Health practices and treatment decisions among Filipino breast cancer patients are widely affected by interplay of the following factors: family, community, doctor’s recommendations, patient’s satisfaction and participation in the decision-making, health care access and adverse treatments to name a few.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bobby de Guzman.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract